Welcome to our dedicated page for AWAKN LIFE SCIENCES news (Ticker: AWKNF), a resource for investors and traders seeking the latest updates and insights on AWAKN LIFE SCIENCES stock.
Awakn Life Sciences Corp. is a clinical-stage biotechnology company focused on developing medication-assisted treatments for addiction, particularly Alcohol Use Disorder (AUD). The company recently completed an investigative study on the dissociative effects of a proprietary S-ketamine formulation, administered orally. This study showed promising results, leading to the designation of program AWKN-002 for AUD treatment in the US market. Awakn has also entered into global licensing agreements and partnerships to advance its innovative therapies.
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) announces recent corporate updates, including regulatory approval for a phase III clinical trial for its lead program AWKN-P001 for the treatment of Severe Alcohol Use Disorder, completion of a feasibility study for its proprietary formulation of MDMA, and engagement with Orphan Insight Ltd. to develop market access for its lead program. The company also closed the fourth tranche of a private placement financing for gross proceeds of $230,000 and $2,964,663 in total for the Offering to date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) announces clinical trial authorization from the MHRA and ethical approval from the Health Research Authority in the UK for a phase III clinical trial for its lead program AWKN-P001, a N-methyl-D-aspartate receptor-modulating drug used in combination with psycho-social support to treat Severe Alcohol Use Disorder (SAUD). The trial will be funded by Awakn, The University of Exeter, and a partnership between the NIHR and the MRC. Enrollment for the phase III is due to start in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
-
Rhea-AI Summary
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) receives notice of non-compliance from Cboe Canada regarding its common stock listing, with 90 days to address the issue. The notice does not impact the company's operations or its focus on advancing psychedelic research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.91%
Tags
Rhea-AI Summary
Awakn Life Sciences has engaged Orphan Insight to develop market access, pricing, and reimbursement for its lead program AWKN-P001, which targets Severe Alcohol Use Disorder (SAUD). AWKN-P001 achieved positive results in a phase II study, with 86% abstinence in the 6 months post-treatment and a 50% reduction in Heavy Drinking Days (HDD) versus placebo. Awakn has received an Innovation Passport from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and has submitted a Clinical Trial Application (CTA) for a phase III trial of AWKN-P001 in the UK. The trial will be run by Awakn, The University of Exeter, and a partnership between NIHR and the MRC, and will be delivered across ten NHS sites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.9%
Tags
-
Rhea-AI Summary
Awakn Life Sciences completes feasibility study confirming stability of MDMA on Catalent's Zydis ODT technology, potentially improving performance and benefiting patients compared to oral capsules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
-
Rhea-AI Summary
Awakn Life Sciences Corp. announces closing of third tranche of private placement and provides corporate update on recent progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
Rhea-AI Summary
Awakn submits Clinical Trial Application for phase III trial of AWKN-P001 for Severe Alcohol Use Disorder (SAUD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.3%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.7%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.5%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of AWAKN LIFE SCIENCES (AWKNF)?
The current stock price of AWAKN LIFE SCIENCES (AWKNF) is $0.065 as of December 13, 2024.
What is the market cap of AWAKN LIFE SCIENCES (AWKNF)?
The market cap of AWAKN LIFE SCIENCES (AWKNF) is approximately 3.1M.
What is Awakn Life Sciences Corp. focused on?
Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing medication-assisted treatments for addiction, with a particular emphasis on Alcohol Use Disorder (AUD).
What recent study did Awakn complete?
Awakn recently completed an investigative study on the dissociative effects of a proprietary S-ketamine formulation administered orally, showing promising results.
What program did Awakn designate for AUD treatment in the US market?
Awakn designated program AWKN-002, involving S-ketamine OTF plus manualized relapse prevention cognitive-behavioral therapy (CBT), for AUD treatment in the US market.
What global licensing agreements has Awakn entered into?
Awakn has entered into global licensing agreements, including one with LTS Lohmann Therapie-Systeme AG, for a proprietary S-ketamine OTF.
What is the strategic focus of Awakn in commercializing its R&D pipeline?
Awakn's strategy is focused on commercializing its R&D pipeline across multiple channels to provide breakthrough therapeutics for addiction sufferers.
What is the goal of Awakn's treatment approach?
Awakn aims to offer efficient and effective treatment options to improve the performance of the addiction industry and provide better outcomes for those suffering from addiction.
Who is Awakn partnering with in the US for treatment expansion?
Awakn has partnered with Rivus Wellness and Research Institute in Oklahoma City to expand treatment options for individuals in need of addiction therapy.
What is the financial status of Awakn?
Awakn has recently closed multiple financing tranches, including private placements and intends to file its annual financial statements by May 30, 2024.
What steps is Awakn taking to address filing delays?
Awakn has applied for a management cease-trade order to address the delayed filing of its financial statements, ensuring transparency and compliance with regulatory requirements.
What information will Awakn provide during the filing delay period?
During the filing delay, Awakn will issue bi-weekly default status reports to keep investors and stakeholders informed about the company's status and developments.
AWAKN LIFE SCIENCES CORP